Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both

Atsunori Nakao, Joao Seda Neto, Shinichi Kanno, Donna B. Stolz, Kei Kimizuka, Fang Liu, Fritz H. Bach, Timothy R. Billiar, Augustine M K Choi, Leo E. Otterbein, Noriko Murase

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Both carbon monoxide (CO) and biliverdin, products of heme degradation by heme oxygenase, have been shown to attenuate ischemia/reperfusion (I/R) injury. We hypothesized in this study that dual-treatment with CO and biliverdin would induce enhanced protective effects against cold I/R injury. Heterotopic heart and orthotopic kidney transplantation were performed in syngeneic Lewis rats after 24-h cold preservation in UW solution. While monotherapy with CO (20 ppm) or biliverdin (50 mg/kg, ip) did not alter the survival of heart grafts, dual-treatment increased survival to 80% from 0% in untreated recipients, with a significant decrease of myocardial injury and improved cardiac function. Similarly, dual-treatment significantly improved glomerular filtration rates of renal grafts and prolonged recipient survival compared to untreated controls. I/R injury-induced up-regulation of pro-inflammatory mediators (e.g. TNF-α, iNOS) and extravasation of inflammatory infiltrates were significantly less with dual-treatment than untreated controls. In addition, dual-treatment was effective in decreasing lipid peroxidation and improving graft blood flow through the distinctive action of biliverdin and CO, respectively. The study shows that the addition of byproducts of heme degradation with different mechanisms of action provides enhanced protection against transplant-associated cold I/R injury of heart and kidney grafts.

Original languageEnglish
Pages (from-to)282-291
Number of pages10
JournalAmerican Journal of Transplantation
Volume5
Issue number2
DOIs
Publication statusPublished - Feb 2005
Externally publishedYes

Fingerprint

Biliverdine
Heart Transplantation
Carbon Monoxide
Reperfusion Injury
Kidney Transplantation
Transplants
Cold Ischemia
Heme
Kidney
Therapeutics
Heme Oxygenase (Decyclizing)
Graft Survival
Glomerular Filtration Rate
Lipid Peroxidation
Up-Regulation
Wounds and Injuries

Keywords

  • Biliverdin
  • Carbon monoxide
  • Cardiac transplantation
  • Heme oxygenase
  • Ischemia/reperfusion injury
  • Renal transplantation

ASJC Scopus subject areas

  • Immunology

Cite this

Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. / Nakao, Atsunori; Neto, Joao Seda; Kanno, Shinichi; Stolz, Donna B.; Kimizuka, Kei; Liu, Fang; Bach, Fritz H.; Billiar, Timothy R.; Choi, Augustine M K; Otterbein, Leo E.; Murase, Noriko.

In: American Journal of Transplantation, Vol. 5, No. 2, 02.2005, p. 282-291.

Research output: Contribution to journalArticle

Nakao, A, Neto, JS, Kanno, S, Stolz, DB, Kimizuka, K, Liu, F, Bach, FH, Billiar, TR, Choi, AMK, Otterbein, LE & Murase, N 2005, 'Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both', American Journal of Transplantation, vol. 5, no. 2, pp. 282-291. https://doi.org/10.1111/j.1600-6143.2004.00695.x
Nakao, Atsunori ; Neto, Joao Seda ; Kanno, Shinichi ; Stolz, Donna B. ; Kimizuka, Kei ; Liu, Fang ; Bach, Fritz H. ; Billiar, Timothy R. ; Choi, Augustine M K ; Otterbein, Leo E. ; Murase, Noriko. / Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. In: American Journal of Transplantation. 2005 ; Vol. 5, No. 2. pp. 282-291.
@article{8d5b2f2dc8f94435b3c1342b5a512bd9,
title = "Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both",
abstract = "Both carbon monoxide (CO) and biliverdin, products of heme degradation by heme oxygenase, have been shown to attenuate ischemia/reperfusion (I/R) injury. We hypothesized in this study that dual-treatment with CO and biliverdin would induce enhanced protective effects against cold I/R injury. Heterotopic heart and orthotopic kidney transplantation were performed in syngeneic Lewis rats after 24-h cold preservation in UW solution. While monotherapy with CO (20 ppm) or biliverdin (50 mg/kg, ip) did not alter the survival of heart grafts, dual-treatment increased survival to 80{\%} from 0{\%} in untreated recipients, with a significant decrease of myocardial injury and improved cardiac function. Similarly, dual-treatment significantly improved glomerular filtration rates of renal grafts and prolonged recipient survival compared to untreated controls. I/R injury-induced up-regulation of pro-inflammatory mediators (e.g. TNF-α, iNOS) and extravasation of inflammatory infiltrates were significantly less with dual-treatment than untreated controls. In addition, dual-treatment was effective in decreasing lipid peroxidation and improving graft blood flow through the distinctive action of biliverdin and CO, respectively. The study shows that the addition of byproducts of heme degradation with different mechanisms of action provides enhanced protection against transplant-associated cold I/R injury of heart and kidney grafts.",
keywords = "Biliverdin, Carbon monoxide, Cardiac transplantation, Heme oxygenase, Ischemia/reperfusion injury, Renal transplantation",
author = "Atsunori Nakao and Neto, {Joao Seda} and Shinichi Kanno and Stolz, {Donna B.} and Kei Kimizuka and Fang Liu and Bach, {Fritz H.} and Billiar, {Timothy R.} and Choi, {Augustine M K} and Otterbein, {Leo E.} and Noriko Murase",
year = "2005",
month = "2",
doi = "10.1111/j.1600-6143.2004.00695.x",
language = "English",
volume = "5",
pages = "282--291",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both

AU - Nakao, Atsunori

AU - Neto, Joao Seda

AU - Kanno, Shinichi

AU - Stolz, Donna B.

AU - Kimizuka, Kei

AU - Liu, Fang

AU - Bach, Fritz H.

AU - Billiar, Timothy R.

AU - Choi, Augustine M K

AU - Otterbein, Leo E.

AU - Murase, Noriko

PY - 2005/2

Y1 - 2005/2

N2 - Both carbon monoxide (CO) and biliverdin, products of heme degradation by heme oxygenase, have been shown to attenuate ischemia/reperfusion (I/R) injury. We hypothesized in this study that dual-treatment with CO and biliverdin would induce enhanced protective effects against cold I/R injury. Heterotopic heart and orthotopic kidney transplantation were performed in syngeneic Lewis rats after 24-h cold preservation in UW solution. While monotherapy with CO (20 ppm) or biliverdin (50 mg/kg, ip) did not alter the survival of heart grafts, dual-treatment increased survival to 80% from 0% in untreated recipients, with a significant decrease of myocardial injury and improved cardiac function. Similarly, dual-treatment significantly improved glomerular filtration rates of renal grafts and prolonged recipient survival compared to untreated controls. I/R injury-induced up-regulation of pro-inflammatory mediators (e.g. TNF-α, iNOS) and extravasation of inflammatory infiltrates were significantly less with dual-treatment than untreated controls. In addition, dual-treatment was effective in decreasing lipid peroxidation and improving graft blood flow through the distinctive action of biliverdin and CO, respectively. The study shows that the addition of byproducts of heme degradation with different mechanisms of action provides enhanced protection against transplant-associated cold I/R injury of heart and kidney grafts.

AB - Both carbon monoxide (CO) and biliverdin, products of heme degradation by heme oxygenase, have been shown to attenuate ischemia/reperfusion (I/R) injury. We hypothesized in this study that dual-treatment with CO and biliverdin would induce enhanced protective effects against cold I/R injury. Heterotopic heart and orthotopic kidney transplantation were performed in syngeneic Lewis rats after 24-h cold preservation in UW solution. While monotherapy with CO (20 ppm) or biliverdin (50 mg/kg, ip) did not alter the survival of heart grafts, dual-treatment increased survival to 80% from 0% in untreated recipients, with a significant decrease of myocardial injury and improved cardiac function. Similarly, dual-treatment significantly improved glomerular filtration rates of renal grafts and prolonged recipient survival compared to untreated controls. I/R injury-induced up-regulation of pro-inflammatory mediators (e.g. TNF-α, iNOS) and extravasation of inflammatory infiltrates were significantly less with dual-treatment than untreated controls. In addition, dual-treatment was effective in decreasing lipid peroxidation and improving graft blood flow through the distinctive action of biliverdin and CO, respectively. The study shows that the addition of byproducts of heme degradation with different mechanisms of action provides enhanced protection against transplant-associated cold I/R injury of heart and kidney grafts.

KW - Biliverdin

KW - Carbon monoxide

KW - Cardiac transplantation

KW - Heme oxygenase

KW - Ischemia/reperfusion injury

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=19944431852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944431852&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2004.00695.x

DO - 10.1111/j.1600-6143.2004.00695.x

M3 - Article

C2 - 15643987

AN - SCOPUS:19944431852

VL - 5

SP - 282

EP - 291

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 2

ER -